Baseline inflammatory profile is associated with short-term antipsychotic-induced weight gain in first-episode psychosis: results from the OPTiMiSE study.
Daphne A M Dielemans, Karin Huizer, Marieke van der Pluijm et al.
✦ AI-curated · Sources linked
In 30 seconds
This analysis of the OPTiMiSE randomised trial examined whether baseline inflammatory markers were associated with short-term antipsychotic-induced weight gain in 208 people with first-episode psychosis treated with amisulpride for four weeks. No individual marker remained significantly associated with weight outcomes after correction for multiple testing. However, a multivariate proteomic profile characterised by lower levels of several immune markers was associated with greater weight gain (β = 0.50, p = 0.017). The findings suggest that baseline immune-related variation may be associated with susceptibility to early weight gain.
Key findings
- No individual inflammatory biomarker was significantly associated with weight outcomes after multiple-testing correction.
- A sparse principal-component proteomic profile was associated with greater weight gain (β = 0.50, p = 0.017).
- The associated profile featured lower baseline levels of several markers, including TNF-α, IL-7, IL-17, GM-CSF, and IFN-γ.
Why it matters
Early weight gain is a clinically important concern when initiating antipsychotic treatment. These results suggest that patterns across immune markers, rather than any single marker, may relate to individual differences in short-term weight change. The association is preliminary and does not establish that inflammation causes weight gain or that biomarker testing can predict it reliably.
What to keep in mind
The study assessed weight change over only four weeks. No individual biomarker association survived multiple-testing correction, and the multivariate profile is an association rather than evidence of causation.